Healthcare Outlook
Asia Pacific Newborn Screening Market is Progressing Towards a Strong Growth By 2026
Infants are most vulnerable to diseases such as polio, epilepsy, encephaliphitis, asthma, COPD and other respiratory disease, diarrhea, leukemia, anemia, and other rare diseases that results in substantial economic burden.
Newborn screening describes various tests that are performed during first few hours or days of an infant’s life. These tests have the potential of preventing severe health problems and prevents from death. According to American Academy of Pediatrics: 2018, newborn screening and diagnosis are important to ensure that all babies who are deaf or hard of hearing are identified as soon as possible. According to same source, 1 to 3 out of every 1,000 babies born in the U.S. have hearing level outside the typical range. When these babies receive early intervention services, it makes a big difference in their communication and language development in the future.
Asia Pacific newborn screening market size was valued at US$ 171.3 million in 2017 and is expected to witness a CAGR of 12.7% during the forecast period (2018 – 2026).
Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2546
Increasing government initiatives is expected to drive growth of the Asia Pacific newborn screening market
Increasing engagement programs by various government healthcare regulatory bodies for newborn screening and its deployment for wider population base are expected to drive growth of the market during the forecast period. For instance, in June 2014, PerkinElmer, a company engaged in the diagnostics, life science research, food, environmental and industrial testing area, entered into an exclusive collaboration with China's National Health and Family Planning Commission (NHFPC) to implement a three-year training program for newborn screening.
The National Maternal & Children Health Surveillance Office (NMCHSO) is working with PerkinElmer, to increase availability and adoption of newborn screening in China, particularly via expansion in more rural areas.
Asia Pacific Newborn Screening Market- Country Analysis
On the basis of country, Asia Pacific newborn screening market is segmented into China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific. China holds the major share due to innovative and new initiatives by government for implementing various newborn screening programs. Currently Congenital Hypothyroidism (CH) and Phenylketonuria (PKU) and hearing loss are included as national wide screening program in China, which is also mandatory for all newborn.
Asia Pacific Newborn Screening Market- Competitive Landscape
Key players operating in the Asia Pacific newborn screening market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.
Detailed Segmentation:
Asia Pacific Newborn Screening Market, By Product Type:
Hearing Screening Devices
Mass Spectrometer
Pulse Oximetry
Assay Kits and Reagents
Asia Pacific Newborn Screening Market, By Test Type:
Phenylketonuria (PKU)
Critical Congenital Heart Defect (CCHD)
Hearing Screening
Sickle Cell Disease
Maple Syrup Urine Disease (MSUD)
Thyroid Disorder
Biotinidase Deficiency (BTD)
Others
Browse In-Depth Analysis Research Report: https://www.coherentmarketinsights.com/market-insight/asia-pacific-newborn-screening-market-2546
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
